Immunohistochemical visualization of pro-inflammatory cytokines and enzymes in ovarian tumors by Plewka, Danuta et al.
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 52, No. 2, 2014
pp. 124–137
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2014
10.5603/FHC.2014.0015
www.fhc.viamedica.pl
ORIGINAL PAPER
Correspondence address: A. Plewka 
Department of Proteomics, Medical University of Silesia, 
Ostrogorska St. 30, 41–200 Sosnowiec 
tel./fax: +48 32 364 14 40 
e-mail: aplewka@sum.edu.pl
*First two authors equally contributed to this paper
Immunohistochemical visualization of pro-inflammatory 
cytokines and enzymes in ovarian tumors 
Danuta Plewka1*, Anna E. Kowalczyk2*, Beata Jakubiec-Bartnik3, Michal Morek3,  
Edyta Bogunia3, Andrzej Kmiec4, Piotr M. Wierzbicki5, Andrzej Plewka3
1Department of Cytophysiology, Chair of Histology and Embryology, Medical University of Silesia, 
Katowice, Poland 
2Department of Human Histology and Embryology, Faculty of Medical Sciences,  
University of Warmia and Mazury, Olsztyn, Poland  
3Department of Proteomics, Medical University of Silesia, Sosnowiec, Poland 
4Division of Oncological Propaedeutics, Medical University of Gdansk, Gdansk, Poland  
5Department of Histology, Medical University of Gdansk, Gdansk, Poland
Abstract: Epithelial ovarian cancer represents one of the most deadly gynaecological neoplasms in developed 
countries and is a highly heterogeneous disease. Epidemiological studies show that anti-inflammatory drugs 
reduce the incidence and mortality of several types of cancer, indicating the potential role of pro-inflammatory 
factors in carcinogenesis. The expression of pro-inflammatory factors in various cancer types, including ovarian 
cancer, was assessed in many studies, yielding inconsistent results, often due to the histological heterogeneity 
of various cancers. The aim of the study was to investigate the expression of IL-1, IL-6, TGF-b, TNF-a, COX-2, 
iNOS, and NF-kB in serous and mucinous ovarian cancers. Ninety cases of ovarian tumors classified into mucous 
and serous type (45 patients in each group) were selected. Each group was classified into subgroups according 
to the three stages of tumor differentiation, i.e. into (i) benign, (ii) borderline and (iii) malignant tumors. The 
presence of proteins of interest in paraffin sections was analysed by immunohistochemistry. The expression of 
most of the studied factors depended on the histological tumor subtype and the degree of malignancy. Expression 
of NF-kB appears to be related to the level of the neoplastic differentiation only in the group of serous tumors, 
while the presence of IL-6 in the mucinous tumor subtype was observed only in the case of benign lesions. 
Expression of IL-1, TNF-a and COX-2 increased with the stage of the disease in both serous and mucinous 
tumors. The highest level of TGF-b expression was observed in serous borderline tumors. The different levels 
of iNOS immunoreactivity between the groups of serous and mucinous tumors were observed only in borderline 
tumors. The results of our study may be helpful in designing therapeutic strategies depending on the type of 
ovarian cancer. (Folia Histochemica et Cytobiologica 2014, Vol. 52, No. 2, 124–137)
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Introduction
Ovarian cancer is the leading cause of death among 
gynaecological neoplasms [1, 2]. Absence of specific 
signs/symptoms of the disease and lack of appropriate 
techniques for population screening causes that in 
over 70% of the cases the disease is diagnosed at its 
advanced stages [3]. Despite significant improvement 
in conventional therapy the healing rate remains low 
for majority of ovarian cancer patients. Therefore, the 
search for new therapeutic strategies targeting specific 
markers continues to better understand a molecular 
background to development of ovarian cancer.
It was found that there was an association between 
chronic inflammation and tumor development and 
progression since ca. 15% of all cancers are attribu-
ted to inflammatory ethiology [4]. Epithelial ovarian 
cancers, similarly to other solid tumors, are strictly 
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associated with inflammation and its regulation by 
a complex cytokine/chemokine network. Cytokines 
are able to regulate growth, signalling, and differen-
tiation of both tumor and stromal cells. It has been 
suggested that the cytokines produced by cancer cells 
create optimal growth conditions within the tumor 
microenvironment, while the cytokines secreted by 
stromal cells may influence the behaviour of mali-
gnant cells [5]. 
Interleukin-1 (IL-1) and IL-6 represent pleio-
tropic cytokines which play a significant role in cell 
proliferation and differentiation, immune protection 
and haematopoiesis [6, 7]. They are also involved in 
malignant transformations and progression of vari-
ous tumors [8, 9]. Interleukin-1 stimulates cells on 
the way of paracrine action to produce IL-6, tumor 
necrosis factor a (TNF-a) and transforming growth 
factor b (TGF-b) [5]. Transforming growth factor b1 
is a multifunctional regulatory polypeptide. Conduct-
ed studies suggest a pro-oncogenic role of TGF-b in 
addition to its tumor suppressor role. The actions of 
TGF-b are dependent on several factors including 
cell type, growth conditions, and the presence of 
other growth factors [10]. The inflammatory cytokine 
TNF-a acts as a significant promoter of a tumor. 
Constitutive TNF-a production by tumor cells may 
generate and sustain a tumor-promoting cytokine 
network in the ovarian cancer microenvironment 
that would aid tumor growth and spread in vivo [11]. 
Stimulation of the ovarian cancer cell proliferation 
by IL-1 can be blocked partially by inhibition of the 
TNF-a action [12]. Tumor necrosis factor a induces 
the IL-6 production [13]. Moreover, together with 
IL-1 TNF-a transcriptionally regulates the expression 
of inducible nitric oxide synthase (iNOS) [14]. The 
role of iNOS during tumor development is highly 
complex. Both promoting and deterring actions have 
been described, presumably depending upon the 
local concentration of iNOS within tumor microenvi-
ronment [15]. One of the role of iNOS in carcinogen-
esis is activation of cyclooxygenase 2 (COX-2) [16]. 
The cyclooxygenase enzyme isoforms 1 and 2 are 
involved in the conversion of arachidonic acid to 
prostaglandins and have distinct functions. Cycloox-
ygenase 1 is constitutively expressed in many tissues, 
while COX-2 is an inducible enzyme expressed only 
in response to stimuli, such as mitogens, cytokines, 
growth factors or hormones, and has pro-inflamma-
tory function. It plays an important role in tumor-
igenesis; COX-2 overexpression is associated with 
apoptosis inhibition, increased invasive and meta-
static potential, and neoangiogenesis. Moreover, it 
has also been hypothesized that overexpression of 
COX-2 could impair host immune response [17, 18]. 
Although many studies have been conducted to eval-
uate the expression of COX-2 in ovarian cancer, their 
results with regard to the association between COX-2 
expression and histological types, prognostic factors, 
response to treatment and outcome are inconsistent. 
Cyclooxygenase 2 expression is induced also by IL-1 
and TNF-a. Sakamoto et al. [19] reported that TNF-
-a-induced COX-2 expression was under the control 
of NF-kB pathway in the ovarian carcinoma. Nuclear 
factor kB (NF-kB) is a transcription factor known 
to promote tumorigenesis. The oncogenic function 
of NF-kB is mainly due to its effect on activation 
of multiple target genes involved in antiapoptosis, 
cell-cycle progression, and angiogenesis. The fact 
that NF-kB mediates the expression of various sur-
vival genes makes it an important target for cancer 
chemotherapy. However, NF-kB is also known to 
be proapoptotic and may potentially function as 
a tumor suppressor [20]. It was previously proposed 
that NF-kB might be required for paclitaxel-induced 
cell death [21]. However, most reports suggest that 
paclitaxel-induced NF-kB activity mediates survival 
signals that counteract apoptosis [22]. Furthermore, 
NF-kB inhibitor sensitizes human ovarian cancer 
cells to the effect of paclitaxel [22], and cispla-
tin [23]. It seems possible that the function of NF-kB 
depends on the tumor type. The activity of NF-kB is 
tightly controlled by several regulatory proteins, e.g. 
TNF-a or IL-1, and the genes regulated by NF-kB 
involve those coding for cytokines (e.g. IL-1, IL-6 or 
TNF-a) [24–27].
Previous studies indicate that each of the histo-
logical subtypes of ovarian cancer may be associated 
with distinct morphologic and molecular genetic 
alterations [28, 29], suggesting that different genes 
or molecular pathways and their importance in the 
progression of various histological subtypes may 
vary significantly. Although many studies have been 
carried out for checking the expression of pro-inflam-
matory agents in various types of cancers, including 
ovarian cancer, the results of these studies have been 
often inconsistent. Therefore, the aim of the present 
study was to investigate the expression of IL-1, IL-6, 
TGF-b, TNF-a, COX-2, iNOS, and NF-kB in the same 
set of tissues originating from benign, borderline and 
malignant ovarian tumors developing on the serous 
or mucinous background.
Material and methods
Patients. Ninety women with epithelium-derived, ovarian 
tumors classified into of mucous (45 patients, mean age 48.1 
± 8.4 years, SEM, range 32–56 years) and serous type (45 
patients, mean age 46.7 ± 7.3 years, range 34–58 years) were 
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included in the study. The two main groups were composed 
of three subgroups (each contained 15 patients) classified 
according to the three stages of tumor differentiation: 
(i) benign tumors, high degree of differentiation, (ii) bor-
derline tumors, medium degree of differentiation, and (iii) 
malignant tumors, low degree of differentiation. Other cli-
nical details were not available. The exclusion criteria were: 
diagnosed tumors of the uterus and other organs, patients 
on hormonal substitute therapy or oral contraceptive drugs, 
patients with autoimmune diseases, pregnant women and 
breast-feeding mothers.
Patients underwent laparotomy at Bielsko-Biala Centre 
of Oncology, Poland. The study was accepted by Bioethical 
Commission of the Silesian Medical University in Katowice, 
Poland (KNW/0022/KB/54/10) and written consent was 
obtained from each patient before treatment. 
Immunohistochemical studies. Tissue samples were fixed in 
10% (v/v) solution of buffered formalin for 24 h at 4°C, and 
then dehydrated, cleared in xylenes and embedded in paraf-
fin. Paraffin sections (5 μm) were mounted on silane-coated 
slides, dewaxed, and rehydrated. The sections were treated 
with 10 mM citrate buffer, pH 6.0 in water bath (30 min at 
95°C) for antigen retrieval, then treated with 1.5% (v/v) 
H2O2 (dissolved in methanol) for 10 min for quenching 
of endogenous peroxidase activity, and washed in 10 mM 
PBS-0.05% v/v Tween 20, pH 7.5. Nonspecific binding was 
reduced by incubation in normal goat serum (for rabbit an-
tibodies) or normal horse serum (for mouse antibodies) for 
30 min. Then slides were incubated with rabbit anti-TGF-b, 
anti-IL-6, anti-TNF-a, anti-iNOS (Abcam, Cambridge, MA, 
USA) and  anti-NF-kB (p65) (Santa Cruz Biotech, Dallas, 
TX, USA) polyclonal antibodies or mouse anti-COX-2 and 
anti-IL-1 (Santa Cruz Biotech) monoclonal antibodies in 
a humidified chamber for 22 h at 4°C. After washing in 
PBS-Tween 20 the sections were incubated with biotinylated 
goat anti-rabbit or horse anti-mouse immunoglobulins 
(Vector Laboratories, Burlingame, CA, USA) for 30 min, 
and next with avidin-biotinylated peroxidase complex (Vec-
tor) for 30 min. The bound antibodies were visualised with 
diaminobenzidine (DAB, Vector) in PBS, pH 7.5 according 
to the manufacturer’s instructions. Finally, the tissues were 
counterstained with Gill’s haematoxilin, dehydrated, and 
cover-slipped. Negative controls were performed by sub-
stituting the primary antibodies with rabbit IgG or mouse 
IgG, respectively. 
The immunohistochemical reactions were documented 
by 10 photographs taken from two representative histologi-
cal slides of each patient using an Eclipse E200 microscope 
with DS-Fi1 digital camera (Nikon, Tokyo, Japan).
Optical density analysis. In each positively stained cell, the 
intensity of staining was measured as the optical density of 
the reaction product, with the image analysis program NIS 
AR (Nikon). For each analysed area an average optical 
density was calculated [30]. Three sections for every studied 
protein and every patient were analysed. In each section 
ten randomly selected fields were examined. Finally, the 
arithmetic mean and standard deviation were calculated.
Statistical analysis. Normal distribution of the data was 
confirmed by the Kolmogorov-Smirnov test. Results were 
presented as a mean ± standard deviation. The Student’s 
t-test was performed. P value < 0.05 was considered to be 
statistically significant.
Results
Immunohistochemical staining demonstrated that 
examined proteins were located in the cytoplasm of 
cells, while NF-kB immunoreactivity was observed in 
both cytoplasm and cell nuclei.
Interleukin 1b
In the group of serous ovarian tumors IL-1 immu-
noreactivity was higher in borderline and malignant 
tumors than in benign lesions by 41% and 61%, re-
spectively (Table 1). However, the immunoexpression 
of IL-1 did not differ between serous malignant and 
borderline tumors.
In the group of mucinous ovarian tumors IL-1 
immunoreactivity in borderline and malignant tumors 
was higher than in benign lesions by 31% and by 86%, 
respectively, (Table 1, Figure 1). Moreover, the IL-1 
expression was by 42% higher in mucinous malignant 
tumors than in mucinous borderline tumors. 
The immunoreactivity of IL-1 in benign, border-
line and malignant lesions was similar in serous and 
mucinous tumors (Table 1, Figure 1). 
Interleukin 6
The immunoreactivity of IL-6 was observed only in 
serous ovarian tumors and in mucinous benign lesions 
(Table 1, Figure 2). No IL-6 expression was found in 
mucinous borderline and malignant tumors.
In serous borderline and malignant ovarian 
tumors IL-6 immunoreactivity was higher by 24% 
and 60%, respectively, than in benign lesions (Ta-
ble 1, Figure 2). Moreover, the IL-6 expression was 
by 29% higher in serous malignant lesions than in 
borderline tumors.
The immunoreactivity of IL-6 in benign lesions 
was similar in serous and mucinous tumors (Table 1, 
Figure 2). 
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Table 1. Quantitative evaluation of protein expression in some ovarian cancer
Protein Serous ovarian tumors Mucinous ovarian tumors
Benign
n = 15
Borderline
n = 15
Malignant
n = 15
Benign
n = 15
Borderline
n = 15
Malignant
n = 15
IL-1 111.5 ± 10.1 157.3 ± 13.8c 179.6 ± 13.9d 100.7 ± 7.8 131.9 ± 11.9f 187.2 ± 14.3g, h
IL-6 110.2 ± 10.6 136.7 ± 12.8c 176.4 ± 14.6d, e 123.3 ± 11.1 – –
TNF-a 102.4 ± 9.8 131.1 ± 1.7c 193.9 ± 12.1d, e 94.2 ± 7.7 143.7 ± 11.5f 186.7 ± 11.9g, h
TGF-b 104.1 ± 1.4 176.1 ± 11.7c 127.8 ± 11.4d, e 83.1 ± 8.8 128.6 ± 11.8b, f 138.3 ± 14.5g
COX-2 84.2 ± 5.7 154.5 ± 12.3c 179.9 ± 13.5d 104.6 ± 9.3a 165.3 ± 12.6f 195.5 ± 11.1g, h
iNOS 141.8 ± 9.3 172.2 ± 9.6c 180.5 ± 12.8d 128.2 ± 8.8 133.4 ± 9.3b 188.4 ± 13.7g, h
NF-kB 99.3 ± 9.2 164.2 ± 11.8c 150.6 ± 9.2d 139.7 ± 10.8a 145.4 ± 9.5b 147.6 ± 9.4
Values represent mean and SEM of densitometric units. Superscripts denote statistically significant difference at P < 0.05, between following 
groups: abenign serous vs. benign mucinous tumors, bborderline serous vs. borderline mucinous tumors, cbenign serous vs. borderline serous 
tumors, dbenign serous vs. malignant serous tumors, eborderline serous vs. malignant serous tumors, fbenign mucinous vs. borderline mucinous 
tumors, gbenign mucinous vs. malignant mucinous tumors, hborderline mucinous vs. malignant mucinous tumors
Figure 1. Immunoreactivity of IL-1 in benign (A, D), borderline (B, E) and malignant (C, F), serous (A, B, C) and mucous 
(D, E, F) ovarian tumors. Magnification × 200
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Tumor necrosis factor a 
In serous borderline and malignant ovarian tumors 
TNF-a  immunoreactivity was higher by 28% and 
89%, respectively, than in benign lesions (Table 1, 
Figure 3). Moreover, the TNF-a expression in ma-
lignant serous lesions was higher by 48% than in 
borderline tumors.
In mucinous tumors TNF-a immunoreactivity in 
borderline and malignant tumors was higher than in 
benign lesions by 53% and 98%, respectively (Table 1, 
Figure 3). Moreover, TNF-a expression in malignant 
mucinous tumors was higher by 30% than in border-
line tumors. 
The immunoreactivity of TNF-a in benign, bor-
derline and malignant lesions was similar in serous 
and mucinous tumors (Table 1, Figure 3). 
Transforming growth factor b
Transforming growth factor b immunoexpression was 
by 69% and 25% higher in borderline and malignant 
serous tumors, respectively, than in borderline tumors, 
and by 38% lower in serous malignant than borderline 
tumors (Table 1, Figure 4).
In mucinous type of ovarian tumors malignant 
and borderline tumors TGF-b immunoexpression 
was by 66% and 55% higher than in benign tumors, 
respectively, and it was at similar level in malignant 
and borderline tumors (Table 1, Figure 4).
In benign and borderline ovarian tumors TGF-b 
immunoreactivity was by 25% and 37% higher in 
the serous than in mucinous tumors, respectively 
and similar in malignant serous and mucous ovarian 
cancer (Table 1, Figure 4).
Figure 2. Immunoreactivity of IL-6 in ovarian tumors. A–F: as described for Figure 1. Magnification × 200
129Expression of pro-inflammatory factors in ovarian cancer
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2014
10.5603/FHC.2014.0015
www.fhc.viamedica.pl
Cyclooxygenase 2
In serous ovarian tumors COX-2 immunoexpression 
was higher in borderline and malignant tumors than 
in benign lesions by 83% and 113%, respectively 
(Table 1, Figure 5). 
In mucinous ovarian tumors COX-2 immuno-
reactivity level in borderline and malignant tumors 
was higher by 58% and 87% than in benign lesions, 
respectively, and at similar level in borderline and 
malignant lesions (Table 1, Figure 5). 
Analysis of COX-2 immunoreactivity in benign 
tumors demonstrated higher immunoexpression of 
COX-2 protein in mucinous tumors than in serous 
ones, and similar expression in serous and mucinous 
borderline and mucinous ovarian cancer (Table 1, 
Figure 5). 
Inducible nitric oxide synthase 
In serous ovarian tumors iNOS immunoexpression 
was higher in borderline and malignant tumors than in 
benign lesions by 21% and 27%, respectively, and was 
at similar level in borderline and malignant tumors 
(Table 1, Figure 6). 
In malignant mucous tumors iNOS immunore-
activity was by ca. 40% higher than in benign and 
borderline tumors. In mucinous borderline tumors 
iNOS immunoreactivity was similar as in the benign 
tumors (Table 1, Figure 6). 
The iNOS immunoreactivity in benign serous and 
mucinous tumors showed a tendency to a higher im-
munoexpression in serous tumors than in mucinous 
ones. In the group of serous tumors iNOS immuno-
reactivity was by 20% and 30% higher in borderline 
Figure 3. Immunoreactivity of TNF-a in ovarian tumors. A–F: as described for Figure 1. Magnification × 200
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and malignant tumors, respectively, than in benign 
lesions (Table 1, Figure 6). In the group of borderli-
ne tumors, iNOS immunoexpression in the group of 
mucinous tumors was by 25% lower than in serous 
tumors (Table 1, Figure 6).
In malignant ovarian tumors iNOS immunoexpres-
sion levels were similar in serous and mucinous tumors.
Nuclear factor kB
In the group of serous tumors NF-kB immunoreac-
tivity was higher in borderline and malignant tumors 
than in benign lesions by 65% and 55%, respectively 
(Table 1, Figure 7).
In mucinous ovarian tumors NF-kB immuno-
expression in benign, borderline and malignant 
tumors was similar (Table 1, Figure 7). 
In malignant ovarian tumors NF-kB immuno-
expression did not differ significantly between serous 
and mucinous tumors. However, in borderline tumors 
the NF-kB immunoreactivity was higher in serous 
than in mucinous tumors. On the contrary, in benign 
tumors the NF-kB immunoreactivity was higher in 
mucinous than in serous tumors (Table 1, Figure 7). 
Discussion
Inflammation is a risk factor for ovarian cancer [31] 
and a hallmark of the most cancers [32]. It has been 
found that the inflammatory response is involved in 
almost all stages of tumor development [33]. Interle-
ukin-1, one of the major pro-inflammatory cytokines, 
plays numerous roles in both physiological and pa-
thological states. It has been reported that IL-1 was 
Figure 4. Immunoreactivity of TGF-b in ovarian tumors. A–F: as described for Figure 1. Magnification × 200
131Expression of pro-inflammatory factors in ovarian cancer
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2014
10.5603/FHC.2014.0015
www.fhc.viamedica.pl
up regulated in melanomas, breast, lung, colon, head 
and neck cancers. Moreover, high IL-1 concentrations 
within the tumor microenvironment were associated 
with a more virulent tumor phenotype and generally 
worse prognosis [5]. Production of IL-1 has been also 
observed in both normal and malignant epithelial 
ovarian cells [34], although activated immune cells in 
the stroma seem to be the major source of IL-1 [35]. 
Our study revealed that expression of IL-1 increased 
with the degree of malignancy and reached the highest 
level in both serous and mucinous metastatic carci-
noma. These results confirm the previously reported 
tumor growth and metastasis promoting functions 
of IL-1. Interleukin-1 has been shown to enhance 
invasion capacities by increasing expression of matrix 
metalloproteinase-1 [36] and stimulating production 
of proangiogenic proteins and growth factors such 
as vascular growth factor [37]. Elevated levels of 
IL-1 may also play a role in tumor cell growth by up 
regulating expression of IL-6 [38, 39]. 
Interleukin-6 stimulates inflammatory cytokine 
production, tumor angiogenesis and tumor macro-
phage infiltrate in ovarian cancer. Furthermore, it 
may also be involved in the tumorigenic processes 
by increasing cancer cells capacity to secrete matrix 
metalloproteinase-9 [40]. Ovarian cancer cell lines 
cultured with IL-6 showed elevated chemotactic and 
chemokinetic activity and increased invasiveness [41]. 
Neoplastic ovarian cells routinely overexpress IL-6 
in vitro [42] and greater amounts of IL-6 are present 
in the cystic fluid of malignant ovarian tumors when 
compared to benign ones [43]. Our studies revealed 
Figure 5. Immunoreactivity of iNOS in ovarian tumors. A–F: as described for Figure 1. Magnification × 200
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that expression of IL-6 in serous ovarian tumors was 
the highest in malignant lesions, while the presence of 
IL-6 in the mucinous tumor subtype was observed only 
in benign lesions. Thus, our observations suggest that 
the role of IL-6 and its regulators in the pathogenesis 
of ovarian cancer may depend on the histological type. 
This observation can be very important in selecting the 
appropriate therapy, because it was that overexpres-
sion of IL-6 was associated with chemoresistance of 
ovarian cancer cells [44, 45], and autocrine production 
of IL-6 decreased responsiveness of these cells to 
cisplatin and paclitaxel [46]. 
Transforming growth factor b is a multifunctional 
regulatory polypeptide with multiplicity of effects 
on tumor growth. It has been proposed that TGF-b 
can act as both a tumor suppressor and significant 
stimulator of tumor progression, invasion and 
metastasis [10]. The actions of TGF-b depend on 
several factors including cell type, growth conditions, 
or presence of other factors/regulators. Increased 
immunoexpression of TGF-b was observed in breast, 
colorectal, pancreas, stomach, brain, and prostate can-
cer, moreover, it correlated with decreased patients’ 
survival [47]. Therefore, it was postulated that TGF-b 
may be considered a biomarker for poor prognosis in 
these malignancies [47]. In our study the immunore-
activity of TGF-b in ovarian cancer depended on the 
histological tumor subtype and the degree of malig-
nancy differentiation. In the case of serous tumors, 
the highest level of TGF-b immunoreactivity was 
observed in borderline tumors suggesting a possible 
role of this growth factor in pathogenesis of this type 
Figure 6. Immunoreactivity of COX2 in ovarian tumors. A–F: as described for Figure 1. Magnification × 200
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Figure 7. Immunoreactivity of NFkB in ovarian tumors. A–F: as described for Figure 1. Magnification × 200
of ovarian lesions. This observation with finding 
of enhanced expression of TGF-b immunoreactiv-
ity in mucinous borderline and malignant tumors 
suggests that pro-oncogenic activities of TGF-b 
predominate over its tumor suppressor actions and 
that overexpression of TGF-b can enhance and 
stimulate tumor growth and malignant progression 
of ovarian cancer. 
Tumor necrosis factor a is the another key mediator 
of inflammation and has been linked to the stimulation 
of tumor initiation and progression, in part by inducing 
the production of angiogenic factors, chemokines/cyto-
kines and matrix metalloproteinases [48]. In previous 
studies, TNF-a mRNA and protein expression was ob-
served predominantly within ovarian tumor epithelial 
islands and a positive correlation was found between 
tumor grade and the extent of TNF-a expression in 
serous ovarian carcinoma [49]. Immunohistochemical 
analysis revealed that TNF-a positivity was confined 
to malignant tissue, while the normal ovarian tissue 
was negative for TNF-a staining [50]. Szlosarek et al. 
reported that expression of TNF-a in ovarian tumors 
was higher compared with normal ovarian tissue, and 
cultured ovarian cancer cells expressed up to 1000 times 
more TNF-a mRNA than cultured normal ovarian 
surface epithelial cells, but TNF-a protein was only 
detected in the supernatant of tumor cell cultures. We 
found that immunoreactivity of TNF-a increased with 
the degree of malignancy and there was no difference 
in its levels between serous and mucinous tumors. 
Results of all these studies confirm the role of TNF-a 
in ovarian cancer development.
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Furthermore, TNF-a is a strong inducer of COX-2 
expression by stimulating the NF-kB system [19]. 
Cyclooxygenase 2 is an early response gene in in-
flammation and there is a growing body of evidence 
that COX-2 expression is important in carcinogene-
sis [51]. Experimental studies showed that COX-2 
inhibitors blocked tumor growth [52]. Moreover, 
epidemiologic studies demonstrated significantly 
lower risk of colorectal carcinoma and several other 
types of cancer in people continuously taking non-
-steroidal anti-inflammatory drugs, which are well 
known COX inhibitors [53]. It was suggested that 
COX-2 may regulate cell proliferation, cell adhesion, 
apoptosis, immune surveillance, and angiogenesis 
during carcinogenesis [51]. Expression of COX-2 was 
observed in various malignancies, including cervical, 
gastrointestinal, head and neck, urinary bladder, and 
lung tumors. It was often associated with metastasis 
and poor prognosis [54–58] as well as with resistance 
to chemotherapeutic agents and radiation [59, 60]. 
In ovarian cancer, studies have reported conflicting 
results regarding the COX-2 expression. Expression 
of COX-2 has been mostly reported to be higher in 
ovarian invasive carcinoma than in tumors with low 
malignant potential [61–65]. Our study also revealed 
the lowest level of COX-2 immunoreactivity in benign 
tumors and the highest in malignant ones. In contrast 
to these results, Klimp et al. [66] observed that COX- 2 
staining was more intense in the epithelial cells of 
benign and borderline tumors than in malignant 
tumors. The study by Dore et al. [67] indicated no 
expression of COX-2 in ovarian tumors. Comparing 
histologic subtypes, we found that the expression of 
COX-2 was higher in mucinous lesions than that in 
serous ones, but this difference was not significant in 
the borderline tumors. Similarly to our observations, 
Yoshida et al. [68] reported the lack of differences 
in the expression of COX-2 between serous and 
mucinous borderline tumors, but in contrast to our 
results they found lower level of COX-2 expression 
in mucinous benign tumors compared to serous 
lesions and no differences in the COX-2 expression 
between serous and mucinous malignant tumors. 
Studies by Ferrandina et al. [18] revealed opposite 
results indicating significantly higher percentage of 
COX-2 positivity in serous borderline tumors than 
in mucinous lesions. It is difficult to explain reasons 
for these discrepancies, but some authors suggest that 
inconsistent results between studies may be due to 
differences in staining assessment, differences in sta-
ining techniques, source of antibody and population 
differences [17, 51]. Although Özel et al. [16] failed 
to detect a correlation between histological type of 
tumor and expression of COX-2, our results confirm 
suggestions of Seo et al. [51] that expression of COX-2 
in ovarian carcinoma is specific to histologic type of 
tumor and COX-2 may enhance the metastatic po-
tential as well as tumorigenicity and may be involved 
in the progression of ovarian tumors [62]. 
Activation of COX-2 is associated with the func-
tion of inducible NOS [16]. iNOS synthesizes nitric 
oxide (NO), which is thought to play various roles in 
physiologic and pathologic conditions. The function 
of NO in tumor biology is complex, because it has 
both inhibitory and stimulatory roles in cellular pro-
cesses depending on the conditions, such as the local 
concentration NO, presence of other regulators, and 
genetic make-up of the cells [69]. NO at high con-
centrations may be cytostatic or cytotoxic for tumor 
cells by causing p53-dependent cell cycle arrest and 
apoptosis [70]. However, NO can also promote tumor 
growth, metastasis and angiogenesis by upregulating 
vascular endothelial growth factor [14]. Expression of 
iNOS can be transcriptionally regulated by cytokines 
such as IL-1 and TNF-a [14], and was observed in 
a variety of human malignant tumors, e.g. breast [71], 
lung [72], prostate [73], bladder [74], and colorec-
tal [75] cancer. Although increased expression of 
iNOS is common in tumors, different studies on 
the same types of tumors reported different results 
both regarding the source of iNOS and the levels of 
expression. The prognostic significance of iNOS in 
cancer is also controversial. It was suggested that 
iNOS expression strongly depended on histological 
type/grade of the tumor and tumor stage [15]. Previ-
ous studies revealed that iNOS activity was localized 
in ovarian malignant tumor tissue and not in benign 
tissue [76]. However, Klimp et al. [66] showed that 
borderline and benign ovarian tumors also expressed 
iNOS. Anttila et al. [77] indicated that iNOS expres-
sion favoured prolonged survival in epithelial ovarian 
cancer and mucinous tumors expressed significantly 
more iNOS than other types, but positive expression 
iNOS was not associated with increased survival in 
this tumor type. Results of our investigations revealed 
significantly higher iNOS expression in borderline and 
malignant serous tumors compared to benign lesions. 
Moreover, the level of iNOS expression was higher 
in serous than in mucinous borderline tumors. In the 
case of mucinous tumors, the highest level of iNOS 
immunoreactivity was observed in malignant lesions. 
Our findings are consistent with studies by Nomelini 
et al. [78] and Ali-Fehmi et al. [2] who showed that 
expression of iNOS was increased in malignant ovarian 
cancer samples compared to non-neoplastic or benign 
tumor samples. It was found that the epithelial ovarian 
cancer cell lines overexpressed iNOS and had high 
baseline NO levels what was associated with high levels 
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of vascular endothelial growth factor production and 
angiogenesis induction [79]. Raspollini et al. reported 
that overexpression of iNOS had a negative impact on 
the response to chemotherapy and overall survival in 
patients with ovarian serous adenocarcinoma [80]. 
Thus, a better understanding of mechanisms which 
control expression and function of iNOS could be use-
ful in the development of more effective therapies that 
will lead to improved cure rates and patient survival. 
It has been shown that mechanisms of iNOS in-
duction involve NF-kB [81]. Nuclear factor kB plays 
an important regulatory role in the transcription of 
genes that may be assigned to the categories of im-
munoregulatory and inflammatory genes, anti-apop-
totic genes, and genes regulating proliferation [82]. 
A deregulated NF-kB pathway is thought to contrib-
ute to tumor progression. NF-kB was found to be 
overexpressed in several cancers, including ovarian 
cancer [83–85]. Guo et al. [83] indicated that elevated 
NF-kB expression significantly correlated with late 
clinical stage and poor histological differentiation. 
Our study revealed higher expression of NF-kB in 
borderline and malignant serous ovarian tumors 
compared to benign lesions, while in the case of the 
mucinous tumors there were no significant differen-
ces in the levels of NF-kB immunoreactivity between 
benign, borderline and malignant lesions. Ali-Fehmi 
et al. [2] demonstrated that NF-kB expression in ep-
ithelial ovarian tumors did not differ by tumor type, 
nor did it influence patients’ outcome. However, in 
their study, nuclear but not cytoplasmic NF-kB was 
used for intensity grading. The classic form of NF-kB 
is normally retained in cytoplasm by its interactions 
with inhibitor proteins IkBa and IkBb, and NF-kB is 
generally considered active when it is present rather in 
nucleus than in cytoplasm [82]. However, the overall 
level of this protein may also be related to its level 
of activity. Annunziata et al. [86] reported that an 
increase in cytoplasmic NF-kB transcription factor 
p50 was significantly associated with poorer patients’ 
survival, but no association was found between NF-kB 
transcription factor p65 and survival. There are five 
members of the mammalian NF-kB/Rel family and 
heterodimer composed of the p50 and 65 subunits is 
the classic form [82]. Therefore, we used anti-NF-kB 
p65 antibodies in our study. Darb-Esfahani et al. [87] 
detected p65 expression mainly in the cytoplasm of 
ovarian carcinoma cells and, in contrast to study by 
Annunziata et al. [86], total p65 expression was an 
indicator of a worse patient outcome. Patients with 
overexpression of p65 had a significantly shorter mean 
survival than those with negative tumors. Results of 
study by Chen et al [88] provided evidences that the 
dual function of NF-kB, as an inhibitor or activator 
of apoptosis, depends on the relative levels of p65 or 
c-Rel subunits, respectively. 
In summary, our studies have shown differences 
in the expression of pro-inflammatory factors and 
their regulators depending on the histological type 
of ovarian cancer and the degree of malignancy. 
Inflammation agents have a wide range of growth 
regulatory effects on cancer cells and they can directly 
or indirectly promote or inhibit tumor growth. Thus, 
better understanding of regulation of their expression 
in different histological types of ovarian cancer may 
help in developing novel strategies for ovarian cancer 
diagnosis and therapy. 
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